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more effective and less costly than latanoprost (25.68% vs. 24.76% IOP reduction 
rate, $603.08 vs. $615.33 expected cost). Thus taﬂuprost was shown to be dominant 
compared with latanoprost. The results of sensitivity analysis revealed stable across 
most of the included parameters. CONCLUSIONS: According to this study, taﬂuprost 
shows better clinical outcome for one year than latanoprost. In addition, frist-line 
treatment of taﬂuprost is a more cost-effective strategy associated with POAG or 
ocular hypertension compared with latanoprost.
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OBJECTIVES: The objective of this study was to evaluate the cost-effectiveness (CE) 
of biologic drugs for the treatment of moderate to severe psoriasis. METHODS: A 
CE model was developed to estimate the incremental cost per quality adjusted life-year 
(QALY) associated with supportive care and each biologic for the treatment of moder-
ate to severe psoriasis (deﬁned by 4th quartile DLQI for purposes of calculating utili-
ties). Treatments were compared using the Psoriasis Area Severity Index (PASI) 50, 
75, and 90 response rates at 10 weeks for inﬂiximab and 12 weeks for the others, 
which were supported by clinical trials and an expert panel. Direct health care costs 
and utilities values were also included in the analysis. The CE analysis was conducted 
by comparing estimates of expected costs and health effects per unit of time for each 
treatment, incorporating both patients who ‘respond’ and continue treatment and 
those who do not ‘respond’ and stop treatment. All data was reviewed by a focus 
group in order to adapt the model to the Spanish clinical practice RESULTS: In the 
base case analysis inﬂiximab is associated with mean expected costs of a5909 and 
mean expected QALYs of 0.216. Respective results were a2947 and 0.100 QALYs 
for etanercept 25 mg, a5433 and 0.173 QALYs for adalimumab and a7,907 and 0,151 
QALYs for etanercept 50 mg. The incremental cost-effectiveness ratio (ICER) was 
a27,320 for inﬂiximab, a29,430 for etanercept, a31,417 for adalimumab and a52,367 
for etanercept 50 mg. CONCLUSIONS: First Inﬂiximab 5 mg/kg (0,2,6 then every 8 
weeks) and then etanercept 25 mg administered twice a week treatments are the most 
cost-effective alternatives from the Spanish National Health System perspective for the 
treatment of moderate to severe psoriasis, both below the a30,000/QALY threshold 
commonly accepted in Spain for the introduction of new technologies.
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OBJECTIVES: The objective of the ‘piggy-back’ trial is to examine the cost-effective-
ness of inﬂiximab compared to etanercept in patients with moderate to severe plaque    
psoriasis or psoriasis vulgaris. Before starting the cost-effectiveness study it is usefull 
to know what to measure and where to invest or aim for. The objective of this paper     
is to estimate the expected value of perfect information (EVPI), with an underlying 
goal of estimating the partial EVPI’s (EVPPI’s) to make a prediction about the value 
of obtaining further information, for all parameters and a partial set of parameters. 
METHODS: Analysis was conducted using a Markov model for patients with moder-
ate to severe plaque psoriasis. For estimating partial EVPI’s (EVPPI’s) a Monte Carlo 
simulation (MCS) method was used. Transition probabilities were calculated, based 
on published evidence, expert opinion, and demographic data. Outcomes expected 
were total societal costs, expected QALY’s and clinical effectiveness. The analysis was 
performed from a partial societal perspective of The Netherlands. The outcome of 
partial EVPI was split into costs, utilities, success rates and dropout rates. RESULTS: 
The cost-effectiveness acceptability curve (CEAC) indicates a high decision uncer-
tainty. The CEAC and EVPI also show inﬂiximab needs a high willingness to pay. 
According to the EVPPI analysis the most uncertainty is seen in utilities (25,239 
million) followed by costs (a4,216 million). Success rates and dropout rates also show 
a high EVPPI but much lower (around 204 and 385 million). CONCLUSIONS: When 
looking at the EVPPI’s there is clearly much interest in investing in research to the 
utilities and the cost of treatment and little interest investing in success rates and 
progress rates. Because indirect costs, like costs of travel and productivity loss, are 
excluded and differ between the two therapies, there can be potential gain by further 
research to the costs.
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OBJECTIVES: Biologic therapies have proven efﬁcacious for patients with moderate-
to-severe psoriasis. However, recommended therapeutic regimens and modes of 
administration differ from agent to agent. For Italy, their economic value compared 
with standard of care has not been explored. This study estimates the cost-effectiveness 
of intermittent therapy with etanercept in patients with moderate-to-severe plaque-
type psoriasis in comparison with non-systemic therapy in Italy. METHODS: This 
study employs cost-utility analysis using a Markov model adapted from the British 
“York model”. It compares intermittent etanercept vs non-systemic therapy in terms 
of cost per Quality-Adjusted Life Year (QALY). Data on efﬁcacy and changes in 
quality of life were derived from three etanercept clinical trials. Direct costs of treating 
psoriasis patients, including hospitalizations and dermatology clinic visits, were taken 
from an Italian cost-of-illness study. Extrapolations were made to evaluate the 
cost-effectiveness of intermittent etanercept vs non-systemic therapy over a period of 
ten years. RESULTS: For the group of patients with moderate and severe plaque 
psoriasis (initial Psoriasis Area and Severity Index PASI q 10) the incremental cost-
effectiveness ratio (ICER) for etanercept compared with non-systemic therapy 
was a33,216/QALY; for the group of patients with severe psoriasis (PASI q 20), the 
ICER was a25,486/QALY. CONCLUSIONS: Within the Italian health care system, 
intermittent etanercept (25 mg twice weekly) is a cost-effective therapeutic option 
compared with non-systemic therapy for the group of patients with moderate and 
severe plaque psoriasis. For patients with PASI q 20 etanercept cost-effectiveness is 
even greater.
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OBJECTIVES: To determine the cost-effectiveness of ustekinumab versus etanercept 
among Canadian adults with severe plaque psoriasis who have an inadequate response, 
are intolerant or contraindicated to at least one conventional systemic therapy. 
METHODS: The York Model, developed to evaluate biologics for the National 
Institute for Health and Clinical Excellence, was adapted to the Canadian environ-
ment. The model consisted of an initial 12-week trial period based on results from 
ACCEPT, an active-control phase III trial which demonstrated superior efﬁcacy of 
ustekinumab versus etanercept. The maintenance period, consisted of the trial results 
extrapolated over a 10-year time horizon. The cost-utility analysis compared estimates 
of expected costs and health effects of ustekinumab 45 mg q12w and etanercept 50 mg       
biw for 12 weeks and qw thereafter. Response was deﬁned as achievement of qPASI 
75 from the ACCEPT trial. Non-responders were switched to supportive care. 
Resource utilization was obtained from the literature and a Delphi panel of Canadian 
dermatologists. Direct health care costs were obtained from the literature and expert 
opinion. Utility was mapped from DLQI to EQ-5D using the algorithm used by the 
York Model. Costs and outcomes were discounted at 5%. RESULTS: Mean annual 
costs and QALYs for ustekinumab were $16,835 and 0.1464 compared to $19,558 
and 0.1419 for etanercept. These results were robust to changes in parameter esti-
mates. Not knowing the costs of adverse events over the 10-year time horizon was a 
limitation of the analysis. Cost-effectiveness acceptability curves show that at all levels 
of willingness- to-pay for one additional unit of efﬁcacy, ustekinumab 45 mg remains   
a more cost-effective treatment option than etanercept. CONCLUSIONS: Ustekinumab 
was more effective and less costly than etanercept over a 10-year time horizon, sug-
gesting that ustekinumab is a dominant treatment option relative to etanercept for the 
treatment of patients with severe plaque psoriasis.
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BACKGROUND: Lack of adherence to drug treatment is a major obstacle to disease 
control. Persistence and compliance are two components of adherence. OBJECTIVES: 
to assess: 1) the proportion of antiglaucoma medication users who persist on their 
treatment after 12 months; 2) the proportion of compliant users among them; and 3) 
the determinants of persistence and of compliance. METHODS: A population-based 
cohort study using the Quebec Health Insurance Board databases. Patients initiated 
on antiglaucoma medication treatment between January 1, 1998, and January 6, 2007 
were included. Patients still undergoing treatment with any antiglaucoma medication 
1 year after their ﬁrst prescription were considered persistent. Of these patients, those 
with a supply of drugs for at least 80% of the days were deemed compliant. A multi-
variate logistic regression model using a stepwise procedure was used to identify the 
characteristics associated with both outcomes. RESULTS: Of 69,461 new users of 
antiglaucoma medication, 41,005 (59%) were persistent after 1 year, and 16,592 
(40.5% of those who persisted) were compliant. Patients more likely to be both per-
sistent and compliant were female and those whose ﬁrst prescription was made by an 
ophthalmologist. Increasing age, living in a rural area, and having initiating glaucoma 
treatment after 2002 were associated with persistence, whereas having used more than 
ﬁve prescription drugs in the year preceding antiglaucoma treatment initiation was 
associated with better compliance. Patients initiated on sympathomimetics, parasym-
pathomimetics, carbonic anhydrase inhibitors, beta blocking agents and on more than 
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one agent were less likely to persist than those initiated on a prostaglandin analog. 
Those initiated on parasympathomimetic, beta blocking agent or on more than one 
agent were less likely to be compliant. Carbonic anhydrase inhibitors users were more 
likely to be compliant. CONCLUSIONS: Among the new antiglaucoma treatment 
users, 24% adhered to their treatment. The initial drug inﬂuences the likelihood of 
both persistence and compliance.
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OBJECTIVES: To assess French patient’s characteristics and ophthalmologists man-
agement of glaucoma in 2009. METHODS: An internet cross-sectional one-day 
 multicentre study led in France aimed at describing management of glaucoma (G)/
ocular hypertension (OHT)—deﬁned by an intraocular pressure q21 mm Hg, and also 
at assessing satisfaction and compliance. RESULTS: Two hundred eighty-eight oph-
thalmologists included 963 patients, 43.2% were male. Open-angle-glaucoma (OAG) 
in 71.7% and OHT in 24.3% of cases were motives for consultation. For OAG and 
OHT mean disease duration was respectively 9.2 o 7.7 years and 5.0 o 5.3 years. 
Mean age was respectively 58.2 o 12.9 and 54.7 o 12.5, mean IOP 17.5 o 4.9 and 
19.1 o 4.2 mm Hg. Average treatment duration was 8.0 o 7.1 years, mean number of 
treatment changes 2.0 o 2.3. Previous treatment consisted in laser in 16.2% of cases, 
surgery 10.5%, laser plus surgery 4.6%. Medical treatment was administered in 
94.0% of OAG patients and in 74.9% of OHT patients. Monotherapy was 50.7% 
of medical treatment, ﬁxed association 16.4%, non-ﬁxed associations 32.9%. In 
monotherapy group, beta-blockers (BB) part was 31.7%, prostaglandins (PG) 50.7% 
and carbonic anhydrase inhibitors CAI 5.9%. In ﬁxed association group BBPG were 
used in 72.5% of cases, BBCAI in 20.3% and BB ADR 6.5%. Whatever is the 
medical treatment, changes are secondary to lack of IOP control, visual ﬁeld or ocular 
imaging worsening, lack of tolerance, then weak compliance. Observed rates of very 
satisﬁed patients between BB group and PG are as follows: 37.2% CI95 [29.4; 45.8] 
vs. 28.9% CI95 [23.6; 34.9], rates of very compliant patients: 65.9% CI95 [57.4; 
73.5] vs. 61% IC95 [54.7; 66.9]. CONCLUSIONS: This study demonstrated the large 
part of medical treatment in OAG/OHT. Among them PG are mostly prescribed in 
monotherapy or ﬁxed association with a high level of satisfaction and compliance 
according physicians.
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OBJECTIVES: Psoriasis is a chronic skin disorder affecting 1,5–3% of population and 
its cost to the society has been estimated between $600 and $900/patient/year. Pre-
scription compliance, adherence to an appropriate follow-up program, and changes 
in patients everyday lives represent an essential approach to reach and maintain clini-
cal remission. Our study wants to measure psoriasis related self-efﬁcacy through a 
questionnaire speciﬁcally developed for this purpose (Psoriasis Empowerment Enquiry 
in the Routinely practice or PEER). METHODS: The study was an observational, 
cross-sectional survey. 240 consecutive psoriatic outpatients were asked to ﬁll the 
questionnaire. The PEER is a 20-item Likert-type questionnaire and generates an 
overall empowerment score obtained by summing individual items; since we have 
deﬁned empowerment as mastering the knowledge about psoriasis, learning from past 
experiences and owning skills to combine both to comply with recommendations of 
physicians, the PEER was conceived with 3 subscales. RESULTS: A total of 223 
respondents were analyzed. Psoriatic patients more than 44 years old reported higher 
values in the overall score (p  0.01) and in the skills subscale score (p  0.03) while 
educational level didn’t affect it. People suffering from psoriasis from more than one 
year had a higher overall (p  0.005) and knowledge subscale (p  0.001) scores but 
no signiﬁcant score differences were recorded comparing the number of consultations; 
psoriatic arthritis cases reported higher scores (p  0.001) than those affected by others 
psoriasis subtype. CONCLUSIONS: patients older than age 44, arthropathic patients 
or cases affected from more than one year reported higher scores reﬂecting a higher 
level of empowerment; psoriatic patients are in great need for self-management of their 
chronic disease. We introduce a questionnaire to survey empowerment among psoria-
tic patients that could represent a useful tool to evaluate the efﬁcacy of any kind of 
interventions in this disabling skin disorder.
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OBJECTIVES: This study was conducted to examine the face and content validity as 
well as psychometric properties of the Eyelash Satisfaction Questionnaire (ESQ) 
among cancer patients. Additionally, the aim was to determine whether the measure-
ment properties were equivalent across non-cancer and cancer patients. METHODS: 
Two focus groups (n  15) were conducted among cancer patients post-chemotherapy 
to examine the validity of the conceptual framework and test the face and content 
validity of the ESQ. A web survey was conducted among adults with cancer. Classical 
Test Theory (CTT) and latent variable modeling techniques were performed using data 
collected from the web survey. Conﬁrmatory Factor Analysis (CFA), Multiple Group 
Structural Equation Modeling (MG-SEM), and Differential Item Functioning (DIF) 
were performed to examine the accuracy and stability of the three domains between 
non-cancer (n  909) and post-chemotherapy cancer samples (n  595) in the US. 
RESULTS: Qualitative analysis of the focus group discussions indicated that the con-
ceptual framework established for cancer patients was similar to that for non-cancer 
patients. Additionally, support was found for the face and content validity of the ESQ. 
Internal consistency was found to be high across all three domains (Cronbach’s 
A  0.93, .90, 0.80) and item-to-domain correlations were high (.55–.84). The factor 
structure of the original survey ﬁt the cancer data well with factor loadings ranging 
from .64 to 93. Measurement invariance models provided good ﬁt to the data 
(NNFI  0.97, RMSEA  0.04). Signiﬁcant DIF was found between the two samples 
on two items but the effect sizes of the differences were small (Cohen’s d’s  0.10) 
and substantively negligible. CONCLUSIONS: The research ﬁndings indicate good 
overall performance of the ESQ among cancer patients providing support for its use 
in this population. Additionally, the measurement properties between non-cancer and 
cancer patients were found to be equivalent.
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OBJECTIVES: It is important that a questionnaire can detect impact on HRQoL when 
the disease is ‘active’ and when is not active in patients with Psoriasis. We have 
developed a new questionnaire where the items have been created to evaluate the 
impact of the disease in different phases. METHODS: In order to deﬁne the main 
dimensions, a literature review and a F.G with 5 dermatologists were performed. A 
semi-structured interview was conducted with 20 patients (10 with active and 10 with 
non active). From the content of the interviews several items were identiﬁed. Each 
item was subsequently rated by the dermatologist. The items were administered to a 
sample of 171 patients (52.1% active and 47.9% non active). A factor analysis and 
a Rasch analysis were performed to obtain the ﬁnal pilot questionnaire before the 
validation study. RESULTS: After qualitative reduction, a 37 items questionnaire was 
obtained (score 0; poor HRQoL to 100; good HRQol) (PSO-LIFE 37). Factor analysis 
identiﬁed 6 dimensions (variance explained of 72.4%). Rasch analysis was used to 
exclude those items with INFIT or OUTFIT  1.30 and 0.70 or redundant with other 
items. This ﬁnal questionnaire (PSO-LIFE 20) has good internal consistency (Cron-
bach’s alpha  0.94). Comparative psychometric performance between PSO-LIFE 37 
and PSO-LIFE 20 showed similar internal consistency (0.97 and 0.94), and item cor-
relation-overall score (0.34–0.82 and 0.35–0.81). PSO-LIFE 20 showed differences 
(p  0.042) with severity of psoriasis and between patients with active and non active 
disease (p  0.01) (high score in patients with mild severity, and in patients with non 
active, which reﬂect good HRQoL). CONCLUSIONS: PSO-LIFE is a new question-
naire of 20 items, with a priori good psychometric properties though validation is 
needed through a formal validation process in a sample of adequate size. Preliminary 
results show that highest impact on HRQoL is observed in patients with active 
disease.
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BACKGROUND: The number of patients with atopic dermatitis is increasing., AD 
in industrialized countries concerns 5 to 20 % of children between 6&7 years old, of 
which nearly 10% still suffer from this disease during adulthood. Consequently; atopic 
dermatitis has become a true public health concern with namely difﬁculties in diag-
nosis and patient’s management. OBJECTIVES: In order to rapidly and effectively 
refer patients with AD to dermatologists or paediatricians, our work has aimed at 
designing and validating a questionnaire of presumed diagnosis of AD METHODS: 
This questionnaire was designed and based on a large review of international scientiﬁc 
literature, in particular from articles about diagnosis criteria by Haniﬁ and Rajka and 
the UK Working Party, interviews of experts and a series of structured interviews of 
patients with AD of different levels of severity, hence forming a rich and structured 
verbatim. RESULTS: A questionnaire, using simple vocabulary, and comprising 20 
questions, has been designed. Answers to each question are dichotomic; the subject 
answering either « yes » or « no », so as to prevent any confusion. During test phase, 
it was found necessary to add « do not know »as a possible answer. 8 questions focus 
on the medical history of the patient and his/her family (parents and brothers/sisters), 
2 questions dealt with difﬁculties in getting to sleep as well as the quality of sleep, 9 
